ストックスクリーナーアプリを入手
16.20
5.05%
-0.98
前日終値:
$17.18
開ける：
$16.03
24時間の取引高:
24,662
Relative Volume:
0.69
時価総額：
$6.22B
収益：
$417.75M
当期純損益:
$32.27M
株価収益率:
166.15
EPS:
0.0975
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-12.25%
1か月 パフォーマンス:
-2.02%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$15.54
$16.82
1週間の範囲:
$15.54
$18.32
52週間の値動き範囲:
$13.61
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
16.22 | 6.22B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.95 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.74 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
558.29 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.72 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.78 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-15 | 開始されました | UBS | Buy |
Telix Pharmaceuticals Ltd Adr (TLX) 最新ニュース
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - Stock Titan
Major Breakthrough: France Grants Approval for Advanced Prostate Cancer Detection Technology - Stock Titan
Telix Delivers Record $186M Q1 Revenue as New FDA-Approved Cancer Imaging Agent Bolsters Portfolio - Stock Titan
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate - GlobeNewswire Inc.
Breakthrough Brain Cancer Treatment Doubles Survival Time: Phase 2 Results Revealed - Stock Titan
Telix's Groundbreaking Prostate Cancer Imaging Tech Secures Nationwide Distribution Network - Stock Titan
Former ARTMS Tech Chief Joins Telix to Lead Next-Gen Radiopharmaceutical Innovation - Stock Titan
Major Board Addition: Ex-GSK and Sanofi Leader Joins Telix Pharmaceuticals - Stock Titan
Revolutionary Cancer Diagnostic Begins Human Trials: First Patient Receives Novel Sarcoma Imaging Agent - Stock Titan
FDA Green Lights Revolutionary Prostate Cancer Detection Tool: What Makes Gozellix a Game-Changer - StockTitan
Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix® - The Capital Club
Paladin Energy Ltd (ASX:PDN) Suspends Operations at Langer Heinrich Mine - The Capital Club
Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market - StockTitan
Telix's Game-Changing Isotope Technology Revolutionizes Cancer Treatment Production - StockTitan
Can Telix's Cancer Therapies Transform Urology Treatment? Top Oncologists Weigh In - StockTitan
Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review - StockTitan
Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting - StockTitan
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan
Clinical Trial Success: Telix's Revolutionary Prostate Cancer Treatment Shows Promising Results - StockTitan
Major Breakthrough: Revolutionary Prostate Cancer Detection Tool Gets UK Green Light - StockTitan
Telix Pharmaceuticals acquires ImaginAb assets and technology - Investing.com
Inside Telix's Strategic $45M ImaginAb Acquisition: Next-Gen Cancer Treatment Pipeline Secured - Stock Titan
Telix Pharmaceuticals Acquires RLS USA in Major $230M Radiopharmacy Network Deal - Stock Titan
ImaginAb Sells Therapeutic Pipeline to Telix Pharmaceuticals, Focuses on CD8 ImmunoPET Development - Stock Titan
Telix Pharmaceuticals Hits Record $517M Revenue, Up 55% as Cancer Imaging Portfolio Expands - Stock Titan
Telix Pharmaceuticals Acquires ImaginAb's Cancer Drug Pipeline in $45M Strategic Deal - StockTitan
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Clayton Utz M&A partner Niro Ananda set to resign; KWM eyed - The Australian Financial Review
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade - Stockhead
UBS bullish on Telix stock—Illuccix growth & therapeutic expansion fuel upside - Investing.com
Key Investors Say Bet on These Stocks at Sohn Australia Conference - BNN Bloomberg
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Telix Pharmaceuticals Debuts on Nasdaq Global Select Market Under TLX Symbol - Stock Titan
Liverpool Partners, Adamantem seek new owner for Plena Healthcare - The Australian Financial Review
Telix spins off radiopharma unit to form Rhine Pharma | Pharmaceutical | The Pharmaletter - The Pharma Letter
Guess which top 100 ASX stock is venturing off to the Nasdaq - The Motley Fool Australia
Telix Files Form 20-F Registration Statement for Nasdaq ADS - Yahoo Finance
Up 66% in FY24, will Telix Pharmaceuticals shares continue? - The Motley Fool Australia
TLX ASX: Telix pulls $300m Nasdaq IPO as investors demand deep discount - AFR
Telix Pharmaceuticals targets $200 million in US IPO - Investing.com
Telix Pharmaceuticals to Acquire IsoTherapeutics Group - Contract Pharma
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Australia's Telix Pharmaceuticals jumps on potential US listing - Reuters.com
3 ASX shares for sustainable investment returns - Rask Media
Radiopharma production facility opens in Belgium - European Pharmaceutical Review
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Queen's University Leads Irish Trial of New Prostate Cancer Treatment - Imaging Technology News
Morningstar | Empowering Investor Success - Morningstar
Telix Pharmaceuticals Ltd Adr (TLX) 財務データ
収益
当期純利益
現金流量
EPS
0.81%
大文字化:
|
ボリューム (24 時間):